#ASCO19: Sanofi sets the stage for a late arrival of their multiple myeloma drug isatuximab — with J&J and Genmab laying in wait
CHICAGO — Pharma giant Sanofi is making a rare appearance in the front ranks of the newsmakers at ASCO this year with the details on their Phase III success story for their multiple myeloma drug isatuximab.
We already knew that the data were in their favor. But we didn’t know the actual results, which set the stage for a likely near-term approval in the US and Europe, where regulators have fielded their applications for a first OK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,200+ biopharma pros reading Endpoints daily — and it's free.